The LEO Foundation

Since 1984, LEO Pharma A/S has been fully owned by the LEO Foundation – making it completely independent of outside investment from shareholders. This allows us to focus our commitment on one stakeholder: patients. 100% of our profits are reinvested in LEO Pharma to discover new patient solutions.

The LEO Foundation is an independent, private institution, which provides the stability needed to plan long-term research and development programs. Without outside stakeholders or interests, we can make fast decisions, foster new ideas, and encourage collaboration across the company.

Learn more about the LEO Foundation >

Key LEO milestones:

Anton 1908
LEO Pharma founded by two Danish pharmacists
  1910
3 employees
  1912
First product, Albyl, is marketed
  1926
80 employees
  1940
Heparin LEO® is launched
Leopenicillin 1945
LEO® Penicillin is marketed
  1958
Rontul® and Centyl® are marketed
  1958-1967
LEO expands to France, Holland, Ireland, the UK, Norway, Sweden and Belgium
  1962
Fucidin® is launched
  1978
One-Alpha® is launched
  1983
The LEO Foundation is established
  1984
LEO Canada opens
  1991
Dovonex® and innohep® are launched
  1994
3000 employees worldwide
Daivobet 2001
Dovobet® is launched
Expansion China 2008
100-year anniversary
Expansion to China
LEO 'Going for Gold' strategy announced
  2010
Operations in Brazil, Japan and Mexico initiated
  2012
Picato® is launched

 

View the full LEO Pharma timeline >